Main > ONCOLOGY (**) > GEJ Cancer MET or R PD-L1+ *** > Treatment > USA. M. PD-1 Binding MAb+

---

USA. M. PD-1 Binding MAb+'s subsections
(*) CN Approval Date: 2021. 09.07
(*) EU CE Mark Date: 2021. 06.29.
+Pt+FluoroPyrimidine Based CT
Company
Generic Name: PembrolizuMAb
Patent>Assignee; Claims; No.; Etc.
PD: Programmed Death
RTM
RTM Web-Site

USA. M. PD-1 Binding MAb+'s products
This section has no products